Skye Montoya

Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127

Skye Montoya, Jessie Bourcier, Mark Noviski et al. · Science · 2024 · 148 citations · Full text

Medicine, Molecular Biology, Oncology +15

Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL)

Alexandra Chirino, Skye Montoya, Anita Safronenka et al. · Genes · 2023 · 30 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy

Shivani Handa, Jeong‐Ok Lee, Andriy Derkach et al. · Blood · 2022 · 21 citations · Full text

Medicine, Hematology, Oncology +8

Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)

Nina Nguyen, Sana Chaudhry, Tulasigeri M. Totiger et al. · npj Precision Oncology · 2022 · 18 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Kinase Dead BTK Mutations Confer Resistance to Covalent and Noncovalent BTK Inhibitors but Are Susceptible to Clinical Stage BTK Degraders

Skye Montoya, Jessie Bourcier, Meghan C. Thompson et al. · Blood · 2022 · 17 citations

Medicine, Molecular Biology, Pharmacology +15